{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-042382","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.115104+00:00","generated_at":"2026-06-11T13:43:17.911727+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Achieve Life Sciences Q2 net loss $8.2M, cash $25.1M; advances cytisinicline NDA submission H1 2024","bullets":["Net loss of $8.2M in Q2 2023; cash, equivalents and restricted cash $25.1M as of June 30, 2023.","Positive Phase 3 ORCA-3 trial confirmed cytisinicline efficacy/safety for smoking cessation in 792 smokers.","Phase 2 ORCA-V1: cytisinicline increased odds of quitting vaping 2.6x vs placebo (31.8% vs 15.1%).","Plan to submit New Drug Application for cytisinicline in first half of 2024.","Raised $16.5M in registered direct offering; refinanced $16.6M SVB debt with maturity to Dec 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-042382","json":"https://secwatch.observer/filing/0000950170-23-042382.json","markdown":"https://secwatch.observer/filing/0000950170-23-042382.md","text":"https://secwatch.observer/filing/0000950170-23-042382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000095017023042382/0000950170-23-042382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000095017023042382/achv-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T13:43:17.911727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09886d3850a4895090df4fe23ecf02f656ce7cf4","claim":"ACHIEVE LIFE SCIENCES, INC. reported second quarter of 2023 results: revenue $25.1 million, net income $8.2 million.","evidence_excerpt":"terminated in connection with the new contingent convertible debt agreement. Financial Results As of June 30, 2023, the company’s cash, cash equivalents, and restricted cash was $25.1 million. Total operating expenses for the three and six months ended June 30, 2023 were $7.7 million and $16.3 million, respectively. Total net loss for the three and six months ended","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/949858/000095017023042382/0000950170-23-042382-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023"},{"label":"Revenue","value":"$25.1 million"},{"label":"Net income","value":"$8.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}